(Q83611060)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21403667%20AND%20SRC:MED&resulttype=core&format=json

25 January 2020

title

Hematology: Rituximab for follicular lymphoma: maintaining an open mind (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21403667%20AND%20SRC:MED&resulttype=core&format=json

25 January 2020

1 reference

1 reference

1

Bruce D Cheson

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21403667%20AND%20SRC:MED&resulttype=core&format=json

25 January 2020

publication date

15 March 2011

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21403667%20AND%20SRC:MED&resulttype=core&format=json

Nature Reviews Clinical Oncology

25 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21403667%20AND%20SRC:MED&resulttype=core&format=json

25 January 2020

volume

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21403667%20AND%20SRC:MED&resulttype=core&format=json

25 January 2020

issue

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21403667%20AND%20SRC:MED&resulttype=core&format=json

25 January 2020

page(s)

257-258

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21403667%20AND%20SRC:MED&resulttype=core&format=json

Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial.

25 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.35

Long-term follow-up of patients with follicular lymphoma receiving single-agent rituximab at two different schedules in trial SAKK 35/98

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.35

Maintenance rituximab after cyclophosphamide, vincristine, and prednisone prolongs progression-free survival in advanced indolent lymphoma: results of the randomized phase III ECOG1496 Study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.35

Rituximab maintenance treatment of relapsed/resistant follicular non-Hodgkin's lymphoma: long-term outcome of the EORTC 20981 phase III randomized intergroup study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.35

Maximizing therapeutic benefit of rituximab: maintenance therapy versus re-treatment at progression in patients with indolent non-Hodgkin's lymphoma--a randomized phase II trial of the Minnie Pearl Cancer Research Network

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.35

Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: results of a prospective randomized phase 3 intergroup trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.35

Maintenance therapy with rituximab leads to a significant prolongation of response duration after salvage therapy with a combination of rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) in patients with recurring and refractory foll

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.35

Randomised phase III study of R-ICE versus R-DHAP in relapsed patients with CD20 diffuse large B-cell lymphoma (DLBCL) followed by high-dose therapy and a second randomisation to maintenance treatment with rituximab or not: an update of the CORAL st

31 March 2020

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/21403667

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1038/NRCLINONC.2011.35

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21403667%20AND%20SRC:MED&resulttype=core&format=json

25 January 2020

1 reference